[
  {
    "title": "多家公司预告年报业绩将大增；信立泰新冠相关药临床试验获批…重要消息还有这些",
    "href": "http://stock.jrj.com.cn/2023/01/04081237257143.shtml",
    "datetime": "2023-01-04 08:12:02",
    "code": "002294"
  },
  {
    "title": "晚间公告全知道：信立泰SAL0133片获得临床试验批准通知书 博敏电子拟投建IGBT陶瓷衬板及IC封装载板生产基地",
    "href": "http://stock.jrj.com.cn/2023/01/03214137256749.shtml",
    "datetime": "2023-01-03 21:41:26",
    "code": "002294"
  },
  {
    "title": "信立泰：SAL0133片获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2023/01/03171137255634.shtml",
    "datetime": "2023-01-03 17:11:16",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL008注射液获批开展晚期实体瘤适应症Ⅰ期临床试验",
    "href": "http://stock.jrj.com.cn/2022/12/29154637246286.shtml",
    "datetime": "2022-12-29 15:46:16",
    "code": "002294"
  },
  {
    "title": "信立泰：SAL0133片药品临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/12/20165037225808.shtml",
    "datetime": "2022-12-20 16:50:41",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：创新小分子药物SAL0133片临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/12/20164137225806.shtml",
    "datetime": "2022-12-20 16:41:06",
    "code": "002294"
  },
  {
    "title": "信立泰：重组全人源抗PCSK9单克隆抗体注射液Ib期临床试验研究揭盲并取得初步统计分析结果",
    "href": "http://stock.jrj.com.cn/2022/12/16173437218591.shtml",
    "datetime": "2022-12-16 17:34:20",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东香港信立泰质押750万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2022/11/24201037164821.shtml",
    "datetime": "2022-11-24 20:10:13",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押750万股",
    "href": "http://stock.jrj.com.cn/2022/11/24173037164173.shtml",
    "datetime": "2022-11-24 17:30:15",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：信立泰器械拟实施股权激励",
    "href": "http://stock.jrj.com.cn/2022/11/23194837161711.shtml",
    "datetime": "2022-11-23 19:48:07",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：自研创新小分子药物SAL0119片临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/11/21165537154528.shtml",
    "datetime": "2022-11-21 16:55:59",
    "code": "002294"
  },
  {
    "title": "信立泰：SAL0107上市申请获得受理",
    "href": "http://stock.jrj.com.cn/2022/11/03155237109684.shtml",
    "datetime": "2022-11-03 15:52:04",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0107上市申请获受理",
    "href": "http://stock.jrj.com.cn/2022/11/03154737109672.shtml",
    "datetime": "2022-11-03 15:47:19",
    "code": "002294"
  },
  {
    "title": "信立泰：SAL0107上市申请获受理",
    "href": "http://stock.jrj.com.cn/2022/11/03154637109627.shtml",
    "datetime": "2022-11-03 15:46:18",
    "code": "002294"
  },
  {
    "title": "信立泰2022年前三季度净利5.39亿同比增长37.64% 投资收益和利息收入增加",
    "href": "http://stock.jrj.com.cn/2022/10/24213237079654.shtml",
    "datetime": "2022-10-24 21:32:41",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：前三季度净利5.39亿元，同比增长37.64%",
    "href": "http://stock.jrj.com.cn/2022/10/24173437078499.shtml",
    "datetime": "2022-10-24 17:34:07",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)： SAL0108已完成Ⅲ期临床所有患者入组",
    "href": "http://stock.jrj.com.cn/2022/10/14174537056652.shtml",
    "datetime": "2022-10-14 17:45:10",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL056已完成Ⅲ期临床所有患者入组",
    "href": "http://stock.jrj.com.cn/2022/10/10161837043922.shtml",
    "datetime": "2022-10-10 16:18:58",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：创新抗肿瘤生物药SAL008注射液临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/10/09171137041827.shtml",
    "datetime": "2022-10-09 17:11:40",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：选举董事叶宇翔为董事长",
    "href": "http://stock.jrj.com.cn/2022/09/23220337018606.shtml",
    "datetime": "2022-09-23 22:03:37",
    "code": "002294"
  },
  {
    "title": "信立泰披露JK07、JK08境外临床试验进展",
    "href": "http://stock.jrj.com.cn/2022/09/07164936980407.shtml",
    "datetime": "2022-09-07 16:49:25",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)披露JK07、JK08境外临床试验进展",
    "href": "http://stock.jrj.com.cn/2022/09/07164336980419.shtml",
    "datetime": "2022-09-07 16:43:39",
    "code": "002294"
  },
  {
    "title": "信立泰：控股子公司生物医疗拟股份制改制",
    "href": "http://stock.jrj.com.cn/2022/08/26164636941116.shtml",
    "datetime": "2022-08-26 16:46:34",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：S086片治疗轻、中度原发性高血压适应症完成所有患者的入组",
    "href": "http://stock.jrj.com.cn/2022/08/16185836905419.shtml",
    "datetime": "2022-08-16 18:58:07",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0112片获批开展成人肥胖患者或超重患者的体重管理适应症Ⅰ期临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/16155636904392.shtml",
    "datetime": "2022-08-16 15:56:42",
    "code": "002294"
  },
  {
    "title": "信立泰披露2022年半年报，实现营收16.68亿元",
    "href": "http://stock.jrj.com.cn/2022/08/10152636886625.shtml",
    "datetime": "2022-08-10 15:26:52",
    "code": "002294"
  },
  {
    "title": "信立泰2022年上半年净利3.48亿同比增长46.94% 制剂业务收入增长",
    "href": "http://stock.jrj.com.cn/2022/08/09223136884672.shtml",
    "datetime": "2022-08-09 22:31:33",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：上半年净利润增46.94%至3.48亿元",
    "href": "http://stock.jrj.com.cn/2022/08/09180436883616.shtml",
    "datetime": "2022-08-09 18:04:58",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0112片获批开展2型糖尿病(T2DM)适应症Ⅰ期临床试验",
    "href": "http://stock.jrj.com.cn/2022/08/05185336874715.shtml",
    "datetime": "2022-08-05 18:53:38",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：自研1类新药SAL0114片完成Ⅰ期临床首例受试者入组",
    "href": "http://stock.jrj.com.cn/2022/07/29161636853892.shtml",
    "datetime": "2022-07-29 16:16:17",
    "code": "002294"
  },
  {
    "title": "信立泰：回购股份期限已届满 共回购2.1%公司股份",
    "href": "http://stock.jrj.com.cn/2022/07/25182436840901.shtml",
    "datetime": "2022-07-25 18:24:49",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：注射用盐酸头孢吡肟(信力威)拟中选全国药品集采",
    "href": "http://stock.jrj.com.cn/2022/07/13204836808830.shtml",
    "datetime": "2022-07-13 20:48:05",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL007获批开展HFpEF适应症I期临床试验",
    "href": "http://stock.jrj.com.cn/2022/07/13155336807353.shtml",
    "datetime": "2022-07-13 15:53:34",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)截至6月底已累计耗资6.02亿元回购2.10%的股份",
    "href": "http://stock.jrj.com.cn/2022/07/01183536776077.shtml",
    "datetime": "2022-07-01 18:35:26",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟使用不超13亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/06/28160436764468.shtml",
    "datetime": "2022-06-28 16:04:23",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：苯甲酸复格列汀片Ⅲ期临床研究已完成揭盲并取得初步的统计分析结果",
    "href": "http://stock.jrj.com.cn/2022/06/23191136754185.shtml",
    "datetime": "2022-06-23 19:11:32",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：S086完成慢性心衰适应症Ⅲ期临床试验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2022/06/23165336753506.shtml",
    "datetime": "2022-06-23 16:53:42",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东香港信立泰质押2100万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2022/06/15201136732338.shtml",
    "datetime": "2022-06-15 20:11:17",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：子公司左心耳封堵器系统获得注册批准",
    "href": "http://stock.jrj.com.cn/2022/06/15193736732177.shtml",
    "datetime": "2022-06-15 19:37:23",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押2100万股",
    "href": "http://stock.jrj.com.cn/2022/06/15174636731706.shtml",
    "datetime": "2022-06-15 17:46:37",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：自研创新小分子化学药物SAL0112片临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/06/09165236716147.shtml",
    "datetime": "2022-06-09 16:52:12",
    "code": "002294"
  },
  {
    "title": "新冠特效药角逐战再添一员，科兴制药“官宣”合作信立泰",
    "href": "http://stock.jrj.com.cn/2022/06/06194336706785.shtml",
    "datetime": "2022-06-06 19:43:55",
    "code": "002294"
  },
  {
    "title": "国产新冠小分子口服药传好消息！深圳科兴牵手信立泰签下新冠口服药委托生产协议，业内：前期量不会很大",
    "href": "http://stock.jrj.com.cn/2022/06/06082536704230.shtml",
    "datetime": "2022-06-06 08:25:40",
    "code": "002294"
  },
  {
    "title": "技术路线与真实生物、君实生物相同！300亿医药股与科兴签下新冠口服药委托生产协议，股价自高位一度腰斩",
    "href": "http://stock.jrj.com.cn/2022/06/06071536704042.shtml",
    "datetime": "2022-06-06 07:15:54",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：与深圳科兴签署抗新冠病毒小分子口服药CDMO技术服务及委托生产协议",
    "href": "http://stock.jrj.com.cn/2022/06/05172436703682.shtml",
    "datetime": "2022-06-05 17:24:39",
    "code": "002294"
  },
  {
    "title": "信立泰：与深圳科兴签署抗新冠病毒小分子口服药CDMO技术服务及委托生产协议",
    "href": "http://stock.jrj.com.cn/2022/06/05161836703549.shtml",
    "datetime": "2022-06-05 16:18:07",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至5月底累计耗资5.90亿元回购2.06%股份",
    "href": "http://stock.jrj.com.cn/2022/06/01154836696845.shtml",
    "datetime": "2022-06-01 15:48:15",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0112片临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/05/30162036689744.shtml",
    "datetime": "2022-05-30 16:20:56",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0108已完成III期临床首例受试者的入组",
    "href": "http://stock.jrj.com.cn/2022/05/26162336681212.shtml",
    "datetime": "2022-05-26 16:23:41",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：自研创新抗肿瘤生物制品JK08在欧洲提交首个CTA",
    "href": "http://stock.jrj.com.cn/2022/05/23154636670319.shtml",
    "datetime": "2022-05-23 15:46:23",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至4月底已累计回购2.01%股份",
    "href": "http://stock.jrj.com.cn/2022/05/05155436569563.shtml",
    "datetime": "2022-05-05 15:54:40",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：子公司的特立帕肽注射液(欣复泰Pro)获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/21162936419360.shtml",
    "datetime": "2022-04-21 16:29:38",
    "code": "002294"
  },
  {
    "title": "信立泰：公司药品SAL007临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2022/04/19162636398645.shtml",
    "datetime": "2022-04-19 16:26:26",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：重组人神经调节蛋白1-抗HER3抗体融合蛋白注射液临试申请获受理",
    "href": "http://stock.jrj.com.cn/2022/04/19161736398584.shtml",
    "datetime": "2022-04-19 16:17:52",
    "code": "002294"
  },
  {
    "title": "信立泰2022年第一季度净利2.37亿同比增长53.09% 财务费用减少",
    "href": "http://stock.jrj.com.cn/2022/04/19051136391881.shtml",
    "datetime": "2022-04-19 05:11:19",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)一季度净利润2.37亿元 同比增长53.09%",
    "href": "http://stock.jrj.com.cn/2022/04/18195436387201.shtml",
    "datetime": "2022-04-18 19:54:10",
    "code": "002294"
  },
  {
    "title": "信立泰2021年净利5.34亿同比增长776.9% 总经理叶宇翔薪酬126.06万",
    "href": "http://stock.jrj.com.cn/2022/03/29181036151112.shtml",
    "datetime": "2022-03-29 18:10:41",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟以自筹资金约2.5亿元向生物医疗增资",
    "href": "http://stock.jrj.com.cn/2022/03/29150636131159.shtml",
    "datetime": "2022-03-29 15:06:53",
    "code": "002294"
  },
  {
    "title": "信立泰2021年销售费用10亿：占营收34% 销售员平均薪酬35.7万研发人员为18.7万",
    "href": "http://stock.jrj.com.cn/2022/03/29123136104123.shtml",
    "datetime": "2022-03-29 12:31:36",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：子公司生物医疗获逾3亿元融资 信达鲲鹏基金领投",
    "href": "http://stock.jrj.com.cn/2022/03/29083536063399.shtml",
    "datetime": "2022-03-29 08:35:31",
    "code": "002294"
  },
  {
    "title": "信立泰2022年第一季度预计净利2.12亿-2.63亿同比增长36%-69% 销售放量、增长较快",
    "href": "http://stock.jrj.com.cn/2022/03/29051036026520.shtml",
    "datetime": "2022-03-29 05:10:32",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)一季度净利润预增36.45%-69.44%",
    "href": "http://stock.jrj.com.cn/2022/03/28223935955235.shtml",
    "datetime": "2022-03-28 22:39:57",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)2021年度净利润升776.9%至5.34亿元 拟10派4元",
    "href": "http://stock.jrj.com.cn/2022/03/28223635955237.shtml",
    "datetime": "2022-03-28 22:36:35",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东解除质押3000万股",
    "href": "http://stock.jrj.com.cn/2022/03/24194034929741.shtml",
    "datetime": "2022-03-24 19:40:20",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：JK07的HFrEF适应症在美I期临床第一组试验揭盲",
    "href": "http://stock.jrj.com.cn/2022/03/07171734538106.shtml",
    "datetime": "2022-03-07 17:17:54",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至2月底已累计回购1.52%股份",
    "href": "http://stock.jrj.com.cn/2022/03/01171434508578.shtml",
    "datetime": "2022-03-01 17:14:52",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0114片获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/02/16154634368049.shtml",
    "datetime": "2022-02-16 15:46:46",
    "code": "002294"
  },
  {
    "title": "A股异动 | 信立泰(002294.SZ)涨约4% 截至1月底已累计耗资3.98亿元回购股份",
    "href": "http://stock.jrj.com.cn/2022/02/07103234298637.shtml",
    "datetime": "2022-02-07 10:32:12",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0107Ⅲ期临床已完成全部临床入组",
    "href": "http://stock.jrj.com.cn/2022/02/06205334296292.shtml",
    "datetime": "2022-02-06 20:53:31",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至1月底累计耗资3.98亿元回购1.33%股份",
    "href": "http://stock.jrj.com.cn/2022/02/06204134296241.shtml",
    "datetime": "2022-02-06 20:41:36",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押1300万股",
    "href": "http://stock.jrj.com.cn/2022/01/20204134179905.shtml",
    "datetime": "2022-01-20 20:41:14",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东香港信立泰质押1300万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2022/01/20203034179864.shtml",
    "datetime": "2022-01-20 20:30:07",
    "code": "002294"
  },
  {
    "title": "信立泰：控股股东香港信立泰所持1300万股质押 占公司总股本比例1.17%",
    "href": "http://stock.jrj.com.cn/2022/01/20170634179163.shtml",
    "datetime": "2022-01-20 17:06:03",
    "code": "002294"
  },
  {
    "title": "信立泰扣非净利预增82倍 发力创新药拥有有效专利授权205项",
    "href": "http://stock.jrj.com.cn/2022/01/20075034176677.shtml",
    "datetime": "2022-01-20 07:50:36",
    "code": "002294"
  },
  {
    "title": "信立泰预增高达80倍 多元化受阻后将集中资金搞研发",
    "href": "http://stock.jrj.com.cn/2022/01/19072234212998.shtml",
    "datetime": "2022-01-19 07:22:00",
    "code": "002294"
  },
  {
    "title": "信立泰预增高达80倍 多元化受阻后将集中资金搞研发",
    "href": "http://stock.jrj.com.cn/2022/01/19072234172591.shtml",
    "datetime": "2022-01-19 07:22:00",
    "code": "002294"
  },
  {
    "title": "信立泰2021年营收30亿元至31亿元：主打产品实现较好的增长",
    "href": "http://stock.jrj.com.cn/2022/01/18095034168318.shtml",
    "datetime": "2022-01-18 09:50:58",
    "code": "002294"
  },
  {
    "title": "信立泰2021年预计净利4.61亿-5.98亿同比增长657%-883% 信立欣等多个产品中标",
    "href": "http://stock.jrj.com.cn/2022/01/17203234166075.shtml",
    "datetime": "2022-01-17 20:32:57",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：2021年度净利预增657.00%-883.23%",
    "href": "http://stock.jrj.com.cn/2022/01/17164234164960.shtml",
    "datetime": "2022-01-17 16:42:15",
    "code": "002294"
  },
  {
    "title": "信立泰：已回购1.08%公司股份 成交总金额约3.28亿元",
    "href": "http://stock.jrj.com.cn/2022/01/04205834124957.shtml",
    "datetime": "2022-01-04 20:58:18",
    "code": "002294"
  },
  {
    "title": "集采“失利” 信立泰拟对子公司计提资产减值准备1.21亿元",
    "href": "http://stock.jrj.com.cn/2022/01/04122834120994.shtml",
    "datetime": "2022-01-04 12:28:45",
    "code": "002294"
  },
  {
    "title": "“开年就被痛击”！300亿医药股突然计提1.21亿元，逾3万股东深夜难眠",
    "href": "http://stock.jrj.com.cn/2022/01/04082434119684.shtml",
    "datetime": "2022-01-04 08:24:50",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：第四季度就桓晨资产组无形资产计提减值准备约1.21亿元",
    "href": "http://stock.jrj.com.cn/2022/01/03175134110827.shtml",
    "datetime": "2022-01-03 17:51:50",
    "code": "002294"
  },
  {
    "title": "信立泰：拟对苏州桓晨计提资产减值准备1.21亿元",
    "href": "http://stock.jrj.com.cn/2022/01/03163734109931.shtml",
    "datetime": "2022-01-03 16:37:10",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：财务负责人刘军辞职 由孔芸接任",
    "href": "http://stock.jrj.com.cn/2022/01/03163534109930.shtml",
    "datetime": "2022-01-03 16:35:04",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：恩那司他片上市申请获受理",
    "href": "http://stock.jrj.com.cn/2022/01/03163034109915.shtml",
    "datetime": "2022-01-03 16:30:45",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：已累计回购1%的股份",
    "href": "http://stock.jrj.com.cn/2021/12/24171834058306.shtml",
    "datetime": "2021-12-24 17:18:00",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：6880.0535万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2021/12/21202634043136.shtml",
    "datetime": "2021-12-21 20:26:47",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0114片临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/12/07194233981226.shtml",
    "datetime": "2021-12-07 19:42:54",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：创新药阿利沙坦酯片续约国家医保目录",
    "href": "http://stock.jrj.com.cn/2021/12/03165033960460.shtml",
    "datetime": "2021-12-03 16:50:26",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至11月底已累计回购0.79%股份",
    "href": "http://stock.jrj.com.cn/2021/12/01185933950969.shtml",
    "datetime": "2021-12-01 18:59:05",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：高瓴祈翼、高瓴祈睿拟合计3亿元投资锦江电子",
    "href": "http://stock.jrj.com.cn/2021/11/29222933940267.shtml",
    "datetime": "2021-11-29 22:29:08",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：红杉瀚辰、太嘉杉合伙等拟投资入股金仕生物",
    "href": "http://stock.jrj.com.cn/2021/11/18173833873182.shtml",
    "datetime": "2021-11-18 17:38:08",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至10月底已累计回购0.78%股份",
    "href": "http://stock.jrj.com.cn/2021/11/01173333798705.shtml",
    "datetime": "2021-11-01 17:33:32",
    "code": "002294"
  },
  {
    "title": "2000万元减值未影响净利润增长 信立泰将结束营收净利润双降“窘境”",
    "href": "http://stock.jrj.com.cn/2021/10/26084933753290.shtml",
    "datetime": "2021-10-26 08:49:00",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)第三季度净利润1.55亿元 同比增长118.75%",
    "href": "http://stock.jrj.com.cn/2021/10/25183233748705.shtml",
    "datetime": "2021-10-25 18:32:23",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至9月底累计耗资2.35亿元回购867.99万股",
    "href": "http://stock.jrj.com.cn/2021/10/08090533655740.shtml",
    "datetime": "2021-10-08 09:05:14",
    "code": "002294"
  },
  {
    "title": "A股异动 | 信立泰(002294.SZ)涨超6%创2个月新高 获得DD01独家许可权",
    "href": "http://stock.jrj.com.cn/2021/09/23103933503509.shtml",
    "datetime": "2021-09-23 10:39:02",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：获得创新药“DD01”于中国大陆地区的独家许可权",
    "href": "http://stock.jrj.com.cn/2021/09/22164733499230.shtml",
    "datetime": "2021-09-22 16:47:47",
    "code": "002294"
  },
  {
    "title": "信立泰：拟将回购股份总额上调至2亿元-4亿元",
    "href": "http://stock.jrj.com.cn/2021/09/06163533392392.shtml",
    "datetime": "2021-09-06 16:35:03",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟增加股份回购金额至2亿-4亿元",
    "href": "http://stock.jrj.com.cn/2021/09/06161633392332.shtml",
    "datetime": "2021-09-06 16:16:42",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：截至8月底已累计回购666.06万股",
    "href": "http://stock.jrj.com.cn/2021/09/01161933367952.shtml",
    "datetime": "2021-09-01 16:19:23",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟终止“nanatinostat”独家许可使用权协议",
    "href": "http://stock.jrj.com.cn/2021/08/23214333305269.shtml",
    "datetime": "2021-08-23 21:43:01",
    "code": "002294"
  },
  {
    "title": "信立泰2021年半年度净利2.37亿元 同比净利增加20.50%",
    "href": "http://stock.jrj.com.cn/2021/08/23203633304866.shtml",
    "datetime": "2021-08-23 20:36:50",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)半年度净利润2.37亿元 同比增长20.5%",
    "href": "http://stock.jrj.com.cn/2021/08/23203333304842.shtml",
    "datetime": "2021-08-23 20:33:34",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)截至7月底已累计回购279.17万股",
    "href": "http://stock.jrj.com.cn/2021/08/02213633190868.shtml",
    "datetime": "2021-08-02 21:36:46",
    "code": "002294"
  },
  {
    "title": "信立泰将花不超2亿元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2021/07/28211433165830.shtml",
    "datetime": "2021-07-28 21:14:59",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：7月28日首次回购55.49万股",
    "href": "http://stock.jrj.com.cn/2021/07/28170633164454.shtml",
    "datetime": "2021-07-28 17:06:58",
    "code": "002294"
  },
  {
    "title": "促进公司长期稳定发展 信立泰拟1亿元至2亿元回购股份",
    "href": "http://stock.jrj.com.cn/2021/07/26103333151132.shtml",
    "datetime": "2021-07-26 10:33:30",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)拟1亿-2亿元回购股份 回购价不超33元/股",
    "href": "http://stock.jrj.com.cn/2021/07/25173733145188.shtml",
    "datetime": "2021-07-25 17:37:15",
    "code": "002294"
  },
  {
    "title": "【龙虎榜】信立泰7月5日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/07/05180633048239.shtml",
    "datetime": "2021-07-05 18:06:30",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)4个产品拟中选第五轮集采",
    "href": "http://stock.jrj.com.cn/2021/06/24115732988652.shtml",
    "datetime": "2021-06-24 11:57:22",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押1560万股及解质2505万股",
    "href": "http://stock.jrj.com.cn/2021/06/22192132977689.shtml",
    "datetime": "2021-06-22 19:21:28",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)披露定增结果：南方基金、睿远基金及财通基金等参投",
    "href": "http://stock.jrj.com.cn/2021/06/21213732971771.shtml",
    "datetime": "2021-06-21 21:37:01",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟转让甲磺酸伊马替尼原料药及其制剂在中国大陆地区的相关权益",
    "href": "http://stock.jrj.com.cn/2021/06/21160332969664.shtml",
    "datetime": "2021-06-21 16:03:57",
    "code": "002294"
  },
  {
    "title": "国药现代(600420.SH)：国药一心拟获信立泰转让甲磺酸伊马替尼原料药及其制剂相关权益",
    "href": "http://stock.jrj.com.cn/2021/06/21153832969465.shtml",
    "datetime": "2021-06-21 15:38:57",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押4100万股及解质9600万股",
    "href": "http://stock.jrj.com.cn/2021/06/18203332956672.shtml",
    "datetime": "2021-06-18 20:33:37",
    "code": "002294"
  },
  {
    "title": "信立泰：控股股东部分股份质押及解除质押",
    "href": "http://stock.jrj.com.cn/2021/06/18193932956316.shtml",
    "datetime": "2021-06-18 19:39:30",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：注射用头孢呋辛钠通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/06/17194632949164.shtml",
    "datetime": "2021-06-17 19:46:14",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：第二期员工持股计划完成非交易过户 涉1750.32万股",
    "href": "http://stock.jrj.com.cn/2021/06/15125132933737.shtml",
    "datetime": "2021-06-15 12:51:22",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：诺泰拟以4500万美元转让MA 13.78%的股权",
    "href": "http://stock.jrj.com.cn/2021/06/15010432929523.shtml",
    "datetime": "2021-06-15 01:04:02",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：阿利沙坦酯吲达帕胺缓释片获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/06/07161132887033.shtml",
    "datetime": "2021-06-07 16:11:18",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押3000万股",
    "href": "http://stock.jrj.com.cn/2021/05/20203932789040.shtml",
    "datetime": "2021-05-20 20:39:25",
    "code": "002294"
  },
  {
    "title": "信立泰(002294)：控股股东股份质押",
    "href": "http://stock.jrj.com.cn/2021/05/20191832789371.shtml",
    "datetime": "2021-05-20 19:18:04",
    "code": "002294"
  },
  {
    "title": "信立泰2021年第一季度净利增长3.31% 市场推广费减少",
    "href": "http://stock.jrj.com.cn/2021/04/20184132411273.shtml",
    "datetime": "2021-04-20 18:41:10",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：一季度净利升3.31%至1.55亿元",
    "href": "http://stock.jrj.com.cn/2021/04/19235832404955.shtml",
    "datetime": "2021-04-19 23:58:19",
    "code": "002294"
  },
  {
    "title": "信立泰2021年第一季度预计净利1.41亿-1.65亿 创新产品业绩增加",
    "href": "http://stock.jrj.com.cn/2021/03/31230432259094.shtml",
    "datetime": "2021-03-31 23:04:19",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)一季度预盈1.41亿元至1.65亿元",
    "href": "http://stock.jrj.com.cn/2021/03/30222432250646.shtml",
    "datetime": "2021-03-30 22:24:07",
    "code": "002294"
  },
  {
    "title": "信立泰2020年净利减少91.49% 总经理叶宇翔薪酬79.77万",
    "href": "http://stock.jrj.com.cn/2021/03/30151032247858.shtml",
    "datetime": "2021-03-30 15:10:04",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟以8000万美元向诺泰增资 用于其新设子公司收购并增资美国Salubris",
    "href": "http://stock.jrj.com.cn/2021/03/30010432244229.shtml",
    "datetime": "2021-03-30 01:04:38",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)2020年净利降91.49%至6086.50万元",
    "href": "http://stock.jrj.com.cn/2021/03/29222832243695.shtml",
    "datetime": "2021-03-29 22:28:34",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：不超7000万股定增计划获批",
    "href": "http://stock.jrj.com.cn/2021/03/09163032097980.shtml",
    "datetime": "2021-03-09 16:30:42",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东香港信立泰质押3000万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2021/02/26101032031465.shtml",
    "datetime": "2021-02-26 10:10:45",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东质押3000万股",
    "href": "http://stock.jrj.com.cn/2021/02/25155132025636.shtml",
    "datetime": "2021-02-25 15:51:49",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：定增申请获证监会审核通过",
    "href": "http://stock.jrj.com.cn/2021/02/22154232006055.shtml",
    "datetime": "2021-02-22 15:42:08",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：替格瑞洛片(60mg)拟中选全国药品集采",
    "href": "http://stock.jrj.com.cn/2021/02/04194031850332.shtml",
    "datetime": "2021-02-04 19:40:03",
    "code": "002294"
  },
  {
    "title": "信立泰2020年预计净利5050.01万-7327.46万下降90%-93% 氯吡格雷产品单价下降",
    "href": "http://stock.jrj.com.cn/2021/01/30154931815088.shtml",
    "datetime": "2021-01-30 15:49:01",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：特立帕肽注射液上市申请获得受理",
    "href": "http://stock.jrj.com.cn/2021/01/19192531723492.shtml",
    "datetime": "2021-01-19 19:25:56",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：SAL0104胶囊临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2021/01/14200931693590.shtml",
    "datetime": "2021-01-14 20:09:04",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰两个复方类降压新药临床试验申请获重要进展",
    "href": "http://stock.jrj.com.cn/2021/01/14000031690262.shtml",
    "datetime": "2021-01-14 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：雷帕霉素药物洗脱冠脉球囊导管完成医疗器械临床试验备案",
    "href": "http://stock.jrj.com.cn/2021/01/12192231677891.shtml",
    "datetime": "2021-01-12 19:22:27",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：阿利沙坦酯吲达帕胺缓释片获得临床试验受理通知书",
    "href": "http://stock.jrj.com.cn/2021/01/10172031662356.shtml",
    "datetime": "2021-01-10 17:20:20",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟为公司董监高购买责任保险，保费不超60万元",
    "href": "http://stock.jrj.com.cn/2021/01/06121331640586.shtml",
    "datetime": "2021-01-06 12:13:09",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟调整回购股份用途",
    "href": "http://stock.jrj.com.cn/2020/12/28181131587346.shtml",
    "datetime": "2020-12-28 18:11:20",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)拟转让盐酸厄洛替尼、利伐沙班内地权益予蓝谷药业",
    "href": "http://stock.jrj.com.cn/2020/12/28180931587342.shtml",
    "datetime": "2020-12-28 18:09:59",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)拟推第二期员工持股计划 募资总额约3.92亿元",
    "href": "http://stock.jrj.com.cn/2020/12/28180631587328.shtml",
    "datetime": "2020-12-28 18:06:50",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：阿利沙坦酯氨氯地平片获批临床试验",
    "href": "http://stock.jrj.com.cn/2020/12/24175031562371.shtml",
    "datetime": "2020-12-24 17:50:06",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：控股股东解除质押5500万股",
    "href": "http://stock.jrj.com.cn/2020/12/21194831538484.shtml",
    "datetime": "2020-12-21 19:48:44",
    "code": "002294"
  },
  {
    "title": "2.8亿商誉减持准备 研发费用减少五成 信立泰难改“单腿走路”",
    "href": "http://stock.jrj.com.cn/2020/12/14085631485147.shtml",
    "datetime": "2020-12-14 08:56:00",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)筹划第二期员工持股计划",
    "href": "http://stock.jrj.com.cn/2020/12/13171031476094.shtml",
    "datetime": "2020-12-13 17:10:24",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟由子公司生物医疗收购雅伦生物股权",
    "href": "http://stock.jrj.com.cn/2020/12/11213031467351.shtml",
    "datetime": "2020-12-11 21:30:06",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：拟以自有资金及子公司股权增资生物医疗",
    "href": "http://stock.jrj.com.cn/2020/12/11212631467318.shtml",
    "datetime": "2020-12-11 21:26:55",
    "code": "002294"
  },
  {
    "title": "信立泰：拟分拆子公司生物医疗至境内证券交易所上市 并计提2.83亿元资产减值准备",
    "href": "http://stock.jrj.com.cn/2020/12/11212531467317.shtml",
    "datetime": "2020-12-11 21:25:34",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：授权启动分拆生物医疗至境内上市的前期筹备工作",
    "href": "http://stock.jrj.com.cn/2020/12/11212331467311.shtml",
    "datetime": "2020-12-11 21:23:26",
    "code": "002294"
  },
  {
    "title": "信立泰：预计明年信立坦的销售会有大幅度的增长",
    "href": "http://stock.jrj.com.cn/2020/12/08190031442052.shtml",
    "datetime": "2020-12-08 19:00:53",
    "code": "002294"
  },
  {
    "title": "信立泰：目前入院超过2500家医院",
    "href": "http://stock.jrj.com.cn/2020/12/08165031440807.shtml",
    "datetime": "2020-12-08 16:50:06",
    "code": "002294"
  },
  {
    "title": "信立泰2名董事合计增持5.64万股 耗资约160.57万元",
    "href": "http://stock.jrj.com.cn/2020/11/19215431318738.shtml",
    "datetime": "2020-11-19 21:54:58",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)已获部分高管增持5.64万股",
    "href": "http://stock.jrj.com.cn/2020/11/19195631318324.shtml",
    "datetime": "2020-11-19 19:56:46",
    "code": "002294"
  },
  {
    "title": "信立泰4名高管合计增持16.72万股 耗资约1006.06万元",
    "href": "http://stock.jrj.com.cn/2020/11/18204431310251.shtml",
    "datetime": "2020-11-18 20:44:32",
    "code": "002294"
  },
  {
    "title": "信立泰2020年前三季度净利2.67亿下滑62.69% 产品销售收入下降",
    "href": "http://stock.jrj.com.cn/2020/10/23091531113914.shtml",
    "datetime": "2020-10-23 09:15:53",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：股份回购期限已届满 累计回购3.28亿元股份",
    "href": "http://stock.jrj.com.cn/2020/10/11172931019530.shtml",
    "datetime": "2020-10-11 17:29:38",
    "code": "002294"
  },
  {
    "title": "[信立泰]雷帕霉素药物洗脱外周球囊导管完成临床试验备案",
    "href": "http://stock.jrj.com.cn/2020/09/29000031690261.shtml",
    "datetime": "2020-09-29 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰(002294.SZ)：雷帕霉素药物洗脱外周球囊导管完成医疗器械临床试验备案",
    "href": "http://stock.jrj.com.cn/2020/09/25201230837256.shtml",
    "datetime": "2020-09-25 20:12:43",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰慢性心衰新药SAL007在中国获批临床",
    "href": "http://stock.jrj.com.cn/2020/09/21000030804283.shtml",
    "datetime": "2020-09-21 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰引入凯雷战略投资",
    "href": "http://stock.jrj.com.cn/2020/09/03000030675594.shtml",
    "datetime": "2020-09-03 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰5%股权作价17.75亿引入凯雷",
    "href": "http://stock.jrj.com.cn/2020/09/02040530656428.shtml",
    "datetime": "2020-09-02 04:05:42",
    "code": "002294"
  },
  {
    "title": "[信立泰]肾性贫血重磅创新产品“恩那司他片”获批中国临床",
    "href": "http://stock.jrj.com.cn/2020/09/02000030675595.shtml",
    "datetime": "2020-09-02 00:00:00",
    "code": "002294"
  },
  {
    "title": "凯雷购入信立泰药业5%股份",
    "href": "http://stock.jrj.com.cn/2020/09/01194430654987.shtml",
    "datetime": "2020-09-01 19:44:51",
    "code": "002294"
  },
  {
    "title": "信立泰引入知名投资公司凯雷集团！双方拟充分发挥生物医疗领域优势达成合作",
    "href": "http://stock.jrj.com.cn/2020/09/01174130654154.shtml",
    "datetime": "2020-09-01 17:41:16",
    "code": "002294"
  },
  {
    "title": "信立泰2020年上半年净利1.97亿减少69% 新产品进院受阻",
    "href": "http://stock.jrj.com.cn/2020/08/27172630605208.shtml",
    "datetime": "2020-08-27 17:26:31",
    "code": "002294"
  },
  {
    "title": "信立泰：2020年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/08/26214030596412.shtml",
    "datetime": "2020-08-26 21:40:01",
    "code": "002294"
  },
  {
    "title": "信立泰3个药品拟中选全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/08/21211130560176.shtml",
    "datetime": "2020-08-21 21:11:52",
    "code": "002294"
  },
  {
    "title": "信立泰获得盐酸帕罗西汀肠溶缓释片药品注册证书",
    "href": "http://stock.jrj.com.cn/2020/08/17193430521047.shtml",
    "datetime": "2020-08-17 19:34:18",
    "code": "002294"
  },
  {
    "title": "[信立泰]重磅!MAURORA雷帕霉素药物洗脱椎动脉支架系统获批上市",
    "href": "http://stock.jrj.com.cn/2020/07/24000030331650.shtml",
    "datetime": "2020-07-24 00:00:00",
    "code": "002294"
  },
  {
    "title": "连续回购市值回涨超百亿 信立泰能否救赎还看新集采",
    "href": "http://stock.jrj.com.cn/2020/07/17081630270375.shtml",
    "datetime": "2020-07-17 08:16:23",
    "code": "002294"
  },
  {
    "title": "信立泰：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/15083030245753.shtml",
    "datetime": "2020-07-15 08:30:03",
    "code": "002294"
  },
  {
    "title": "信立泰2020年上半年预计净利1.9亿元–2.21亿元同比下降 门诊量及手术数量急剧下降",
    "href": "http://stock.jrj.com.cn/2020/07/14191930240694.shtml",
    "datetime": "2020-07-14 19:19:05",
    "code": "002294"
  },
  {
    "title": "信立泰：带量采购价格趋同 上半年净利预降65%-70%",
    "href": "http://stock.jrj.com.cn/2020/07/14170130239129.shtml",
    "datetime": "2020-07-14 17:01:08",
    "code": "002294"
  },
  {
    "title": "每经数说丨6月下半月新药研发：兴齐眼药苦熬18年拿下干眼症药物批文，信立泰能否借恩那司他片弯道超车？",
    "href": "http://stock.jrj.com.cn/2020/07/07121730165096.shtml",
    "datetime": "2020-07-07 12:17:36",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东再质押2480万股 业绩承压“一条腿走路”急需改变",
    "href": "http://stock.jrj.com.cn/2020/06/22081629986267.shtml",
    "datetime": "2020-06-22 08:16:00",
    "code": "002294"
  },
  {
    "title": "信立泰控股股东香港信立泰质押2480万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2020/06/19204129968897.shtml",
    "datetime": "2020-06-19 20:41:59",
    "code": "002294"
  },
  {
    "title": "信立泰：增资入股越光医疗及获得产品代理经销权",
    "href": "http://stock.jrj.com.cn/2020/03/24190129096487.shtml",
    "datetime": "2020-03-24 19:01:00",
    "code": "002294"
  },
  {
    "title": "信立泰：增资入股越光医疗 获得产品代理经销权",
    "href": "http://stock.jrj.com.cn/2020/03/24185229096411.shtml",
    "datetime": "2020-03-24 18:52:17",
    "code": "002294"
  },
  {
    "title": "信立泰2019年盈利7.09亿元下滑51% 研发费用增加",
    "href": "http://stock.jrj.com.cn/2020/02/28230228917892.shtml",
    "datetime": "2020-02-28 23:02:35",
    "code": "002294"
  },
  {
    "title": "信立泰获得盐酸莫西沙星片药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/02/28191828916413.shtml",
    "datetime": "2020-02-28 19:18:29",
    "code": "002294"
  },
  {
    "title": "信立泰：JK07获得美国FDA药品临床试验批准",
    "href": "http://stock.jrj.com.cn/2020/02/24160628882736.shtml",
    "datetime": "2020-02-24 16:06:13",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰美国公司治疗慢性心衰新药JK07获FDA临床许可",
    "href": "http://stock.jrj.com.cn/2020/02/24000028898934.shtml",
    "datetime": "2020-02-24 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰支持肺炎疫情防控工作：向疫区捐赠200万元药品及医疗用品",
    "href": "http://stock.jrj.com.cn/2020/02/04091628763648.shtml",
    "datetime": "2020-02-04 09:16:26",
    "code": "002294"
  },
  {
    "title": "信立泰业绩预减五成 4+7带量采购未中标业绩难恢复增长",
    "href": "http://stock.jrj.com.cn/2020/01/23082528725808.shtml",
    "datetime": "2020-01-23 08:25:00",
    "code": "002294"
  },
  {
    "title": "信立泰：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/23073028725370.shtml",
    "datetime": "2020-01-23 07:30:00",
    "code": "002294"
  },
  {
    "title": "信立泰预计2019年盈利6.56亿元至8.02亿元 同比减少45%至55%",
    "href": "http://stock.jrj.com.cn/2020/01/22175528721647.shtml",
    "datetime": "2020-01-22 17:55:23",
    "code": "002294"
  },
  {
    "title": "信立泰：2019年度净利同比预降45%-55%",
    "href": "http://stock.jrj.com.cn/2020/01/22160628721097.shtml",
    "datetime": "2020-01-22 16:06:57",
    "code": "002294"
  },
  {
    "title": "信立泰：预计2019年净利润6.5亿元-8亿元 同比下降约50%",
    "href": "http://stock.jrj.com.cn/2020/01/22155728721049.shtml",
    "datetime": "2020-01-22 15:57:27",
    "code": "002294"
  },
  {
    "title": "信立泰：公司奥美沙坦酯片拟中选全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/01/19194828702179.shtml",
    "datetime": "2020-01-19 19:48:27",
    "code": "002294"
  },
  {
    "title": "信立泰：奥美沙坦酯片拟中选全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/01/19174628701944.shtml",
    "datetime": "2020-01-19 17:46:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]转载 ┃ 质量引领信立泰扬帆远航",
    "href": "http://stock.jrj.com.cn/2020/01/13000028676607.shtml",
    "datetime": "2020-01-13 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰再次入选“2018年度中国化药企业百强”",
    "href": "http://stock.jrj.com.cn/2020/01/13000028676610.shtml",
    "datetime": "2020-01-13 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰获肾性贫血重磅创新产品独家许可使用权",
    "href": "http://stock.jrj.com.cn/2020/01/08000028676609.shtml",
    "datetime": "2020-01-08 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰获得创新化合物“Enarodustat”独家许可使用权",
    "href": "http://stock.jrj.com.cn/2019/12/25214328586940.shtml",
    "datetime": "2019-12-25 21:43:41",
    "code": "002294"
  },
  {
    "title": "信立泰：获得“Enarodustat”独家许可使用权",
    "href": "http://stock.jrj.com.cn/2019/12/25213328586901.shtml",
    "datetime": "2019-12-25 21:33:09",
    "code": "002294"
  },
  {
    "title": "信立泰：获得“Enarodustat”在肾性贫血适应证领域的独家许可使用权",
    "href": "http://stock.jrj.com.cn/2019/12/25210428586944.shtml",
    "datetime": "2019-12-25 21:04:00",
    "code": "002294"
  },
  {
    "title": "信立泰：获头孢呋辛酯片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/12/19213428558963.shtml",
    "datetime": "2019-12-19 21:34:32",
    "code": "002294"
  },
  {
    "title": "信立泰获得头孢呋辛酯片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/12/19212928559763.shtml",
    "datetime": "2019-12-19 21:29:48",
    "code": "002294"
  },
  {
    "title": "信立泰：获得头孢呋辛酯片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/12/19203128558922.shtml",
    "datetime": "2019-12-19 20:31:00",
    "code": "002294"
  },
  {
    "title": "信立泰：新款心血管药物S086片获临床许可",
    "href": "http://stock.jrj.com.cn/2019/12/16190728541667.shtml",
    "datetime": "2019-12-16 19:07:45",
    "code": "002294"
  },
  {
    "title": "信立泰：S086片获得临床许可 适用于治疗原发性高血压患者",
    "href": "http://stock.jrj.com.cn/2019/12/16185528541428.shtml",
    "datetime": "2019-12-16 18:55:49",
    "code": "002294"
  },
  {
    "title": "信立泰：阿利沙坦酯被纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2019/11/28203328465039.shtml",
    "datetime": "2019-11-28 20:33:35",
    "code": "002294"
  },
  {
    "title": "信立泰创新药阿利沙坦酯被纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2019/11/28201228464958.shtml",
    "datetime": "2019-11-28 20:12:44",
    "code": "002294"
  },
  {
    "title": "信立泰：创新药阿利沙坦酯被纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2019/11/28200528464888.shtml",
    "datetime": "2019-11-28 20:05:00",
    "code": "002294"
  },
  {
    "title": "核心业务折戟！信立泰溢价回购恐难提振股价",
    "href": "http://stock.jrj.com.cn/2019/11/13085028391908.shtml",
    "datetime": "2019-11-13 08:50:00",
    "code": "002294"
  },
  {
    "title": "信立泰：左乙拉西坦片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2019/11/01205228340817.shtml",
    "datetime": "2019-11-01 20:52:31",
    "code": "002294"
  },
  {
    "title": "信立泰第三季度盈利8438万 同比下滑77%",
    "href": "http://stock.jrj.com.cn/2019/10/29141428317495.shtml",
    "datetime": "2019-10-29 14:14:02",
    "code": "002294"
  },
  {
    "title": "信立泰营收净利润双负增长 加大研发投入急于“补课”",
    "href": "http://stock.jrj.com.cn/2019/10/29083928315706.shtml",
    "datetime": "2019-10-29 08:39:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰首个生物制品“注射用重组特立帕肽”获批上市",
    "href": "http://stock.jrj.com.cn/2019/10/16000028676608.shtml",
    "datetime": "2019-10-16 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰子公司获注射用重组特立帕肽药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/10/15180628251116.shtml",
    "datetime": "2019-10-15 18:06:13",
    "code": "002294"
  },
  {
    "title": "信立泰：获注射用重组特立帕肽药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/10/15172928250894.shtml",
    "datetime": "2019-10-15 17:29:53",
    "code": "002294"
  },
  {
    "title": "信立泰：获得注射用重组特立帕肽药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/10/15170628250782.shtml",
    "datetime": "2019-10-15 17:06:00",
    "code": "002294"
  },
  {
    "title": "信立泰落标氯吡格雷集中采购 或致行业竞争格局重塑",
    "href": "http://stock.jrj.com.cn/2019/09/27001928187092.shtml",
    "datetime": "2019-09-27 00:19:11",
    "code": "002294"
  },
  {
    "title": "采扩围竞标正在进行 京新药业、信立泰闪崩跌停",
    "href": "http://stock.jrj.com.cn/2019/09/24132528172367.shtml",
    "datetime": "2019-09-24 13:25:23",
    "code": "002294"
  },
  {
    "title": "【信立泰】大幅拉升0.67% 股价创近2个月新高",
    "href": "http://stock.jrj.com.cn/2019/09/12093228125868.shtml",
    "datetime": "2019-09-12 09:32:50",
    "code": "002294"
  },
  {
    "title": "信立泰2019年上半年盈利6.3亿 销售、财务费用同比增长",
    "href": "http://stock.jrj.com.cn/2019/08/27000928036661.shtml",
    "datetime": "2019-08-27 00:09:52",
    "code": "002294"
  },
  {
    "title": "信立泰：2019年半年度报告主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/08/26214028035819.shtml",
    "datetime": "2019-08-26 21:40:04",
    "code": "002294"
  },
  {
    "title": "信立泰：奥美沙坦酯片获药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/07/30182227904828.shtml",
    "datetime": "2019-07-30 18:22:25",
    "code": "002294"
  },
  {
    "title": "信立泰：获得奥美沙坦酯片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/07/30181727904806.shtml",
    "datetime": "2019-07-30 18:17:04",
    "code": "002294"
  },
  {
    "title": "信立泰股东质押4000万股 公司去年净利同比增长0.44%",
    "href": "http://stock.jrj.com.cn/2019/07/12072227829958.shtml",
    "datetime": "2019-07-12 07:22:06",
    "code": "002294"
  },
  {
    "title": "[信立泰]扶贫济困,善行济众|信立泰药业爱心认捐800万助力“广东扶贫济困日”",
    "href": "http://stock.jrj.com.cn/2019/07/03000027791999.shtml",
    "datetime": "2019-07-03 00:00:00",
    "code": "002294"
  },
  {
    "title": "医药白马信立泰之痛：产品青黄不接 研发投入处理激进",
    "href": "http://stock.jrj.com.cn/2019/06/21155327738694.shtml",
    "datetime": "2019-06-21 15:53:52",
    "code": "002294"
  },
  {
    "title": "[信立泰]匹伐他汀钙片成功上市,信立泰集齐降脂、降压、抗栓产品",
    "href": "http://stock.jrj.com.cn/2019/04/30000028068227.shtml",
    "datetime": "2019-04-30 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]匹伐他汀钙片成功上市,信立泰集齐降脂、降压、抗栓产品",
    "href": "http://stock.jrj.com.cn/2019/04/30000027601059.shtml",
    "datetime": "2019-04-30 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰股东香港信立泰质押5500万股 公司去年净利同比增长0.44%",
    "href": "http://stock.jrj.com.cn/2019/04/26182427492668.shtml",
    "datetime": "2019-04-26 18:24:29",
    "code": "002294"
  },
  {
    "title": "信立泰2019年第一季度净利3.22亿元 董事长叶澄海未持有公司股份",
    "href": "http://stock.jrj.com.cn/2019/04/24064227471293.shtml",
    "datetime": "2019-04-24 06:42:43",
    "code": "002294"
  },
  {
    "title": "信立泰：盐酸贝那普利片通过一致性评价 为国内首家",
    "href": "http://stock.jrj.com.cn/2019/04/19191627429905.shtml",
    "datetime": "2019-04-19 19:16:00",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年实施10派8元 股权登记日4月15日",
    "href": "http://stock.jrj.com.cn/2019/04/08180227347156.shtml",
    "datetime": "2019-04-08 18:02:58",
    "code": "002294"
  },
  {
    "title": "信立泰：匹伐他汀钙片获注册批件",
    "href": "http://stock.jrj.com.cn/2019/03/15203627174841.shtml",
    "datetime": "2019-03-15 20:36:00",
    "code": "002294"
  },
  {
    "title": "信立泰：获得匹伐他汀钙片（2mg）药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/03/15203227174817.shtml",
    "datetime": "2019-03-15 20:32:10",
    "code": "002294"
  },
  {
    "title": "信立泰去年营收46.52亿同比增12% 董事长叶澄海年薪19万元",
    "href": "http://stock.jrj.com.cn/2019/03/13072727158029.shtml",
    "datetime": "2019-03-13 07:27:41",
    "code": "002294"
  },
  {
    "title": "信立泰一季度业绩预降超10% 员工持股计划依然被套",
    "href": "http://stock.jrj.com.cn/2019/03/13014427156193.shtml",
    "datetime": "2019-03-13 01:44:57",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年度拟10派8元",
    "href": "http://stock.jrj.com.cn/2019/03/11205927148141.shtml",
    "datetime": "2019-03-11 20:59:45",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年净利同比微增 拟10派8元",
    "href": "http://stock.jrj.com.cn/2019/03/11205927148163.shtml",
    "datetime": "2019-03-11 20:59:00",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年净利14.58亿元 拟10派8元",
    "href": "http://stock.jrj.com.cn/2019/03/11205127148123.shtml",
    "datetime": "2019-03-11 20:51:01",
    "code": "002294"
  },
  {
    "title": "信立泰2018年度净利润同比增长0.44% 拟10派8元",
    "href": "http://stock.jrj.com.cn/2019/03/11205027148126.shtml",
    "datetime": "2019-03-11 20:50:24",
    "code": "002294"
  },
  {
    "title": "信立泰：地氯雷他定片（5mg）首家通过一致性评价",
    "href": "http://stock.jrj.com.cn/2019/03/04201727116168.shtml",
    "datetime": "2019-03-04 20:17:57",
    "code": "002294"
  },
  {
    "title": "信立泰：获左乙拉西坦缓释片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/02/27205027098704.shtml",
    "datetime": "2019-02-27 20:50:40",
    "code": "002294"
  },
  {
    "title": "信立泰：获得左乙拉西坦缓释片药品注册批件",
    "href": "http://stock.jrj.com.cn/2019/02/27202127098629.shtml",
    "datetime": "2019-02-27 20:21:00",
    "code": "002294"
  },
  {
    "title": "信立泰：氯吡格雷拟中选4+7城市药品集中采购",
    "href": "http://stock.jrj.com.cn/hotstock/2018/12/10080025488951.shtml",
    "datetime": "2018-12-10 08:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰：氯吡格雷拟中选4+7城市药品集中采购",
    "href": "http://stock.jrj.com.cn/2018/12/07202125473104.shtml",
    "datetime": "2018-12-07 20:21:41",
    "code": "002294"
  },
  {
    "title": "信立泰：获“nanatinostat”独家许可",
    "href": "http://stock.jrj.com.cn/2018/11/28210325417916.shtml",
    "datetime": "2018-11-28 21:03:42",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/28202025269088.shtml",
    "datetime": "2018-10-28 20:20:00",
    "code": "002294"
  },
  {
    "title": "信立泰：子公司获重组胰高血糖素样肽-1-Fc融合蛋白注射液药物临床试验批件",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/25080025256979.shtml",
    "datetime": "2018-10-25 08:00:02",
    "code": "002294"
  },
  {
    "title": "信立泰：替格瑞洛原料药获GMP证书",
    "href": "http://stock.jrj.com.cn/hotstock/2018/09/10080025067987.shtml",
    "datetime": "2018-09-10 08:00:01",
    "code": "002294"
  },
  {
    "title": "信立泰：替格瑞洛原料药获GMP证书",
    "href": "http://stock.jrj.com.cn/2018/09/07183025063828.shtml",
    "datetime": "2018-09-07 18:30:00",
    "code": "002294"
  },
  {
    "title": "信立泰获得药品GMP证书",
    "href": "http://stock.jrj.com.cn/2018/09/07182525063795.shtml",
    "datetime": "2018-09-07 18:25:46",
    "code": "002294"
  },
  {
    "title": "增速下滑 分分钟腰斩！老板电器VS信立泰 为啥差异大？",
    "href": "http://stock.jrj.com.cn/2018/09/06080425055244.shtml",
    "datetime": "2018-09-06 08:04:15",
    "code": "002294"
  },
  {
    "title": "信立泰：业绩符合预期 产品线迅速丰富",
    "href": "http://stock.jrj.com.cn/2018/08/27105125004325.shtml",
    "datetime": "2018-08-27 10:51:00",
    "code": "002294"
  },
  {
    "title": "信立泰：制剂增速上升通道 受益于集采试点",
    "href": "http://stock.jrj.com.cn/2018/08/22102424985014.shtml",
    "datetime": "2018-08-22 10:24:00",
    "code": "002294"
  },
  {
    "title": "信立泰：18Q2氯吡格雷收入增速出现波动",
    "href": "http://stock.jrj.com.cn/2018/08/21145424981158.shtml",
    "datetime": "2018-08-21 14:54:00",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/08/20230024977585.shtml",
    "datetime": "2018-08-20 23:00:10",
    "code": "002294"
  },
  {
    "title": "信立泰：上半年净利同比增8% 获北上资金增持",
    "href": "http://stock.jrj.com.cn/2018/08/20212024977146.shtml",
    "datetime": "2018-08-20 21:20:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰上榜 “最具创新力10强”“医药最具竞争力20强”",
    "href": "http://stock.jrj.com.cn/2018/08/06000025062428.shtml",
    "datetime": "2018-08-06 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]喜讯!信立泰重磅产品泰仪(替格瑞洛)获批上市!",
    "href": "http://stock.jrj.com.cn/2018/08/06000025062427.shtml",
    "datetime": "2018-08-06 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰上榜 《E药经理人》评选“最具创新力10强”“医药最具竞争力20强”",
    "href": "http://stock.jrj.com.cn/2018/08/06000027284834.shtml",
    "datetime": "2018-08-06 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰获得替格瑞洛片药品注册批件",
    "href": "http://stock.jrj.com.cn/2018/08/02182624896785.shtml",
    "datetime": "2018-08-02 18:26:17",
    "code": "002294"
  },
  {
    "title": "信立泰：获得替格瑞洛片药品注册批件",
    "href": "http://stock.jrj.com.cn/2018/08/02175524896643.shtml",
    "datetime": "2018-08-02 17:55:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰等八药企发起成立“一致性评价在行动组织”,推动仿制药发展",
    "href": "http://stock.jrj.com.cn/2018/07/17000025062422.shtml",
    "datetime": "2018-07-17 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]信立泰投资并购桓晨医疗 加强心血管领域器械布局",
    "href": "http://stock.jrj.com.cn/2018/06/19000025062418.shtml",
    "datetime": "2018-06-19 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]“关注高血压患者尿酸水平,推动高血压规范诊疗”——信立泰助力TURE项目启动A",
    "href": "http://stock.jrj.com.cn/2018/06/19000025062423.shtml",
    "datetime": "2018-06-19 00:00:00",
    "code": "002294"
  },
  {
    "title": "泰嘉增长承压 信立泰“买买买”拼医械版图",
    "href": "http://stock.jrj.com.cn/2018/06/12042924666179.shtml",
    "datetime": "2018-06-12 04:29:33",
    "code": "002294"
  },
  {
    "title": "信立泰：拟4.73亿元收购苏州桓晨 完善心血管领域产品线",
    "href": "http://stock.jrj.com.cn/hotstock/2018/06/04110424633492.shtml",
    "datetime": "2018-06-04 11:04:59",
    "code": "002294"
  },
  {
    "title": "信立泰拟4.73亿元受让苏州桓晨100%股权",
    "href": "http://stock.jrj.com.cn/2018/06/01215424627819.shtml",
    "datetime": "2018-06-01 21:54:05",
    "code": "002294"
  },
  {
    "title": "信立泰：拟4.73亿元收购苏州桓晨 完善心血管领域产品线",
    "href": "http://stock.jrj.com.cn/2018/06/01212024627709.shtml",
    "datetime": "2018-06-01 21:20:00",
    "code": "002294"
  },
  {
    "title": "信立泰全资子公司拟入股瑞士MA公司",
    "href": "http://stock.jrj.com.cn/2018/05/21222124570292.shtml",
    "datetime": "2018-05-21 22:21:15",
    "code": "002294"
  },
  {
    "title": "信立泰：获得雷帕霉素药物洗脱球囊独家许可",
    "href": "http://stock.jrj.com.cn/2018/05/21210024570075.shtml",
    "datetime": "2018-05-21 21:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]医药创新 品牌引领——信立泰受邀参加首届中国自主品牌博览会",
    "href": "http://stock.jrj.com.cn/2018/05/21000025062425.shtml",
    "datetime": "2018-05-21 00:00:00",
    "code": "002294"
  },
  {
    "title": "5月3日早间公告：信立泰子公司拟400万美元参股美国心血管介入医疗器械公司",
    "href": "http://stock.jrj.com.cn/2018/05/03094624485277.shtml",
    "datetime": "2018-05-03 09:46:00",
    "code": "002294"
  },
  {
    "title": "信立泰子公司拟400万美元参股美国心血管介入医疗器械公司",
    "href": "http://stock.jrj.com.cn/2018/05/03085124484803.shtml",
    "datetime": "2018-05-03 08:51:00",
    "code": "002294"
  },
  {
    "title": "早间公告：信立泰参股美心血管器械公司",
    "href": "http://stock.jrj.com.cn/2018/05/03085024484774.shtml",
    "datetime": "2018-05-03 08:50:39",
    "code": "002294"
  },
  {
    "title": "早间公告：信立泰参股美国心血管介入医疗器械公司",
    "href": "http://stock.jrj.com.cn/2018/05/03083524484708.shtml",
    "datetime": "2018-05-03 08:35:00",
    "code": "002294"
  },
  {
    "title": "信立泰子公司参股美心脑血管介入医疗器械公司",
    "href": "http://stock.jrj.com.cn/2018/05/03080224484595.shtml",
    "datetime": "2018-05-03 08:02:20",
    "code": "002294"
  },
  {
    "title": "医药板块大幅回落 恒瑞医药跌幅超3%",
    "href": "http://stock.jrj.com.cn/2018/04/17145724402384.shtml",
    "datetime": "2018-04-17 14:57:45",
    "code": "002294"
  },
  {
    "title": "信立泰：使用自有资金增资诺泰国际有限公司",
    "href": "http://stock.jrj.com.cn/hotstock/2018/04/17075924399765.shtml",
    "datetime": "2018-04-17 07:59:58",
    "code": "002294"
  },
  {
    "title": "信立泰：2018年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/04/16212024397398.shtml",
    "datetime": "2018-04-16 21:20:00",
    "code": "002294"
  },
  {
    "title": "信立泰：硫酸氢氯吡格雷片（25mg）通过一致性评价",
    "href": "http://stock.jrj.com.cn/2018/04/11181324376085.shtml",
    "datetime": "2018-04-11 18:13:57",
    "code": "002294"
  },
  {
    "title": "信立泰业绩增速放缓 两子公司合计亏损1.23亿",
    "href": "http://stock.jrj.com.cn/2018/04/09025324359163.shtml",
    "datetime": "2018-04-09 02:53:19",
    "code": "002294"
  },
  {
    "title": "信立泰：18年进入在研产品收获期",
    "href": "http://stock.jrj.com.cn/2018/03/28102824312895.shtml",
    "datetime": "2018-03-28 10:28:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]增资潮涌,喜迎开门红",
    "href": "http://stock.jrj.com.cn/2018/01/30000025062424.shtml",
    "datetime": "2018-01-30 00:00:00",
    "code": "002294"
  },
  {
    "title": "[海翔药业]信立泰专利挑战成功-阿斯利康替格瑞洛晶型专利被宣告全部无效",
    "href": "http://stock.jrj.com.cn/2018/01/15000023949287.shtml",
    "datetime": "2018-01-15 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]为泰嘉疯狂打call,祝贺泰嘉首批通过一致性评价",
    "href": "http://stock.jrj.com.cn/2018/01/02000025062415.shtml",
    "datetime": "2018-01-02 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]叶宇翔总经理荣获“2017广东省最具社会责任感企业家”荣誉称号",
    "href": "http://stock.jrj.com.cn/2017/12/27000025062414.shtml",
    "datetime": "2017-12-27 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]全心如一,关爱随行",
    "href": "http://stock.jrj.com.cn/2017/12/22000025062410.shtml",
    "datetime": "2017-12-22 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰：降压药信立坦将开始放量 实现良好效益",
    "href": "http://stock.jrj.com.cn/2017/12/21084523828580.shtml",
    "datetime": "2017-12-21 08:45:00",
    "code": "002294"
  },
  {
    "title": "苏州金盟长期亏损 信立泰执意增资为哪般？",
    "href": "http://stock.jrj.com.cn/2017/12/19173223818034.shtml",
    "datetime": "2017-12-19 17:32:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]喜讯!信立泰荣获“中国红十字博爱奖章”",
    "href": "http://stock.jrj.com.cn/2017/12/19000025062432.shtml",
    "datetime": "2017-12-19 00:00:00",
    "code": "002294"
  },
  {
    "title": "信立泰 质量+创新 医药新时代焕发新生 强烈推荐评级",
    "href": "http://stock.jrj.com.cn/2017/12/15140523798405.shtml",
    "datetime": "2017-12-15 14:05:00",
    "code": "002294"
  },
  {
    "title": "信立泰：拟对控股子公司苏州金盟增资5.5亿元",
    "href": "http://stock.jrj.com.cn/hotstock/2017/12/05075923740525.shtml",
    "datetime": "2017-12-05 07:59:59",
    "code": "002294"
  },
  {
    "title": "[信立泰]国家卫计委科教司监察专员刘登峰率队调研信立泰",
    "href": "http://stock.jrj.com.cn/2017/12/01000025062413.shtml",
    "datetime": "2017-12-01 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]国家食药监总局药品评价中心领导、专家莅临信立泰调研",
    "href": "http://stock.jrj.com.cn/2017/11/24000025062420.shtml",
    "datetime": "2017-11-24 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]世客会上,香港行政长官林郑月娥向叶澄海董事长颁发“钻石纪念奖”",
    "href": "http://stock.jrj.com.cn/2017/10/18000025062409.shtml",
    "datetime": "2017-10-18 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]凝心聚力 致胜未来——信立泰新产品及专科药总部2017年中管理会",
    "href": "http://stock.jrj.com.cn/2017/09/25000025062421.shtml",
    "datetime": "2017-09-25 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]科技创新 共襄盛举——信立泰参加深圳国际BT领袖峰会和生物/生命健康产业展览会",
    "href": "http://stock.jrj.com.cn/2017/09/22000025062417.shtml",
    "datetime": "2017-09-22 00:00:00",
    "code": "002294"
  },
  {
    "title": "[信立泰]聆听业内顶级声音,共享跨国学术盛宴",
    "href": "http://stock.jrj.com.cn/2017/09/22000025062419.shtml",
    "datetime": "2017-09-22 00:00:00",
    "code": "002294"
  }
]